The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 12, 2012, Pages 1531-1548

  Rangel, Erika B ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Immunosuppressive drugs; Metabolic adverse effects; Pancreas transplant; Toxicological effects

Indexed keywords

CALCINEURIN INHIBITOR; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METRONIDAZOLE; MYCOPHENOLIC ACID; NORFLOXACIN; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACNE; ANEMIA; BONE DISEASE; BONE MARROW SUPPRESSION; CATARACT; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; DIABETES MELLITUS; DYSLIPIDEMIA; EYE DISEASE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFERTILITY; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL PNEUMONIA; KIDNEY PANCREAS TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LYMPHOCELE; MALAISE; METABOLIC PARAMETERS; MOUTH ULCER; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEW ONSET DIABETES MELLITUS AFTER TRANSPLANT; NEW ONSET OF DIABETES MELLITUS AFTER TRANSPLANT; OVARY CYST; PANCREAS TRANSPLANTATION; PEPTIC ULCER; PROTEINURIA; RASH; REPRODUCTIVE TOXICITY; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TOXICOLOGICAL PARAMETERS; TOXICOLOGY; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ADRENAL CORTEX HORMONES; BONE DISEASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL DISEASES; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOLOGIC DISEASES; HUMANS; HYPERKALEMIA; HYPERURICEMIA; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NERVOUS SYSTEM DISEASES; PANCREAS TRANSPLANTATION; PNEUMONIA; RENAL INSUFFICIENCY, CHRONIC; SIROLIMUS;

EID: 84869456744     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.724058     Document Type: Review

References (138)

1. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25, 000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011;8(1):6-16
2. Sollinger HW, Odorico JS, Becker YT, et al. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg 2009;250(4):618-30
3. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1, 000 pancreas transplants at a single institution. Ann Sur 2001; 233(4):463-501
4. Fridell JA, Mangus RS, Hollinger EF, et al. The case for pancreas after kidney transplantation. Clin Transplant 2009;23(4):447-53
5. Pavlakis M, Khwaja K, Mandelbrot D, et al. Renal allograft failure predictors after PAK transplantation: results from the New England Collaborative Association of Pancreas Programs. Tranplantation 2010;89(11):1347-53
6. Browne S, Gill J, Dong J, et al. The impact of pancreas transplantation on kidney allograft survival. Am J Transplant 2011;11(9):1951-8
7. Bazerbachi F, Selzner M, Marquez MA, et al. Portal venous versus systemic venous drainage of pancreas grafts: impact on long-term results. Am J Transplant 2012;12(1):226-32
8. Drachenberg CB, Papadimitriou JC, Farney A, et al. Pancreas transplantation: the histologic morphology of graft loss and clinical correlations. Transplantation 2001;71(12):1784-91
9. Waki K, Terasaki PI, Kadowaki T. Long-term pancreas allograft survival in simultaneous pancreas-kidney transplantation by era: UNOS registry analysis. Diabetes Care 2010;33 (8):1789-91
10. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011;11(9):1792-802
11. Rangel EB, Melaragno CS, Sá JR, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation. Transplant Proc 2009;41(10):4265-9
12. Cantarovich D, Vistoli F. Minimization protocols in pancreas transplantation. Transpl Int 2009;22(1):61-8
13. Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011;24(12):1216-30
14. Neidlinger N, Singh N, Klein C, et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant 2010;10(2):398-406
15. Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. Transpl Int 2009;22(5):519-30
16. Rangel EB, Melaragno CS, Neves MD, et al. Family history of diabetes as a new determinant of insulin sensitivity and secretion in patients who have undergone a simultaneous pancreas-kidney transplant. Exp Clin Transplant 2010;8(1):29-37
17. Ozbay LA, Møller N, Juhl C, et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol 2012;73(4):536-45
18. Gillard P, Vandemeulebroucke E, Keymeulen B, et al. Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients. Transplantation 2009; 87(3):402-7
19. P, PetruzzoBadet L, Lefrançois N, et al. Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med 2006, 23(6):654-9
20. Petruzzo P, Laville M, Badet L, et al. Effect of venous drainage site on insulin action after simultaneous pancreas-kidney transplantation. Transplantation 2004; 77(12):1875-9
21. Stadler M, Anderwald C, Pacini G, et al. Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver. Diabetes 2010;59(1):215-18
22. Rooney DP, Robertson RP. Hepatic insulin resistance after pancreas transplantation in type I diabetes. Diabetes 1996;45(2):134-8
23. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004;15(12):3233-9
24. Rangel EB, Melaragno CS, de Sá JR, et al. Risk factors for the development of posttransplantation diabetes mellitus in simultaneous pancreas and kidney recipients. Transplant Proc 2004; 36(4):982-3
25. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72(10):1655-61
26. Boots JM, van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13(1):221-7
27. van Duijnhoven EM, Christiaans MH, Boots JM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002;13(1):213-20
28. Drachenberg CB, Klassen DK, Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999;68(3):396-402
29. Secchi A, Malaise J, Caldara R. Euro-SPK Study Group. Metabolic results 3 years after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005; 20(Suppl 2):ii18.24; ii62
30. Havrdova T, Jedinakova T, Lipar K, et al. Effect of tacrolimus versus cyclosporine on glucose metabolism of pancreas and kidney recipients in the late (>8years) posttransplant period. Transplant Proc 2011;43(9):3270-2
31. Van Laecke S, Van Biesen W, Verbeke F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009;9(9):2140-9
32. Nijenhuis T, Hoenderop JG, Bindels RJ. Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004;15(3):549-57
33. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16(10):3128-35
34. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation 2006; 82(4):466-70
35. Zhang N, Su D, Qu S, et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 2006;55(9):2429-36
36. Sun CL, Ham DS, Park HS, et al. Rapamycin suppresses the expansion and differentiation of porcine neonatal pancreas cell clusters. Transplantation, 2010;90(7):717-24
37. Song HK, Han DH, Song JH, et al. Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats. Am J Transplant 2009;9(9):2024-33
38. Gao R, Ustinov J, Korsgren O, Otonkoski T. Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. Am J Transplant 2007;7(4):1021-6
39. F€oger B, K€onigsrainer A, Palos G, et al. Effect of pancreas transplantation on lipoprotein lipase, postprandial lipemia, and HDL cholesterol. Transplantation 1994;58(8):899-904
40. F€oger B, K€onigsrainer A, Ritsch A, et al. Pancreas transplantation modulates reverse cholesterol transport. Transpl Int 1999;12(5):360-4
41. Lauria MW, Figueiró JM, Machado LJ, et al. The impact of functioning pancreas-kidney transplantation and pancreas alone transplantation on the lipid metabolism of statin-naïve diabetic patients. Clin Transplant 2009; 23(2):199-205
42. Stahlschmidt A, Suzigan BH, Martins CC, et al. Simultaneous pancreas-kidney transplantation: evaluation of graft function, cholesterol, triglycerides, and immunosuppressive regimens. Transplant Proc 2009; 41(3):916-18
43. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002;43(8):1170-80
44. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008;52(2):324-30
45. Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 2010;23(12):1191-204
46. Nikkel LE, Hollenbeak CS, Fox EJ, et al. Risk of fractures after renal transplantation in the United States. Transplantation 2009;87(12):1846-51
47. Patel S, Kwan JT, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 2001; 16(10):1863-70
48. Smets YF, van der Pijl JW, de Fijter JW, et al. Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 1998; 13(5):1250-5
49. Chiu MY, Sprague SM, Bruce DS, et al. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 1998;9(4):677-83
50. Smets YF, de Fijter JW, Ringers J, et al. Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int 2004;66(5):2070-6
51. Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients-a review. Am J Nephrol 2008; 28(2):246-53
52. Bozkaya G, Nart A, Uslu A, et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Transplant Proc 2008; 40(1):151-5
53. Casez JP, Lippuner K, Horber FF, et al. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002; 17(7):1318-26
54. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18(10):1319-28
55. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
56. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005;45(4):638-49
57. Coco M, Glicklich D, Faugere MC, et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003;14(10):2669-76
58. Goffin E, Devogelaer JP, Lalaoui A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002;15(2-3):73-80
59. ter Meulen CG, van Riemsdijk I, Hené RJ, et al. No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. Transplantation 2004;78(1):101-6
60. Pereira S, Pedroso S, Martins L, et al. Bone mineral density after simultaneous kidney-pancreas transplantation: four years follow-up of 57 recipients. Transplant Proc 2010;42(2):555-7
61. Yeo H, Beck LH, McDonald JM, Zayzafoon M. Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone 2007;40(6):1502-16
62. Maes B, Hadaya K, de Moor B, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study. Am J Transplant 2006;6(6):1466-72
63. Davies NM, Grinyó J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 2007;22(9):2440-8
64. Mycophenolate mofetil for treatment of a first acute renal allograft rejection: a three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 2001;71(8):1091-7
65. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate Mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000;69(11):2239-40
66. Gruessner RW, Sutherland DE, Drangstveit MB, et al. Mycophenolate mofetil in pancreas transplantation. Transplantation(1998):66(3):318-23
67. Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation (2000):69(5):875-80
68. Squifflet JP, Bäckman L, Claesson K, et al. European Tacrolimus-MMF Renal Study Group. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72(1):63-9
69. Behrend M. Adverse gastrintestinal effects of mycophenolate Mofetil: aetiology, incidence, and management. Drug Saf 2001;24(9):645-63
70. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14(9):2381-6
71. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate Mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006;82(1):102-7
72. Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis 2008;51(3):478-486.
73. T, Hellervan Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant 2007; 7(7):1822-31
74. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26(5):1553-79
75. Khurana A, McCuskey CF, Slavcheva EG. Orthostatic hypotension in kidney pancreas transplant patients and its relation to preexisting autonomic neuropathy. Exp Clin Transplant 2008; 6(2):127-31
76. Salvadori M, Holzer H, de Mattos A, et al. ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004;4(2):231-6
77. Budde K, Curtis J, Knoll G, et al. ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4(2):237-43
78. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19(2):199-206
79. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007;7(4):888-98
80. Budde K, Glander P, Krämer BK, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 2007; 83(4):417-24
81. Pescovitz MD, Vincenti F, Hart M, et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol 2007;64(6):758-71
82. W, LemahieuMaes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005;5(6):1383-91
83. WP, LemahieuMaes BD, Vanrenterghem Y. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. Transplant Proc 2005;37(5):2051-3
84. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006;28(1):39-44
85. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349(24):2326-33
86. Nankivell BJ, Wavamunno MD, Borrows RJ, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007; 7(2):366-76
87. Genzini T, Marchini GS, Chang AJ, et al. Influence of pancreas transplantation alone on native renal function. Transplant Proc 2006; 38(6):1939-40
88. Fioretto P, Najafian B, Sutherland DE, Mauer M. Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients. Clin J Am Soc Nephrol 2011;6(1):101-6
89. Boggi U, Vistoli F, Amorese G, et al. Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients. Rev Diabet Stud 2011;8(2):259-67
90. Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008;21(2):152-5
91. Laham G, Sleiman S, Soler Pujol G, et al. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients. Transplant Proc 2010;42(1):309-13
92. Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 2011;91(9):997-1004
93. Liefeldt L, Brakemeier S, Glander P, et al. Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus with Cyclosporine After Kidney Transplantation. Am J Transplant 2012;12(5):1192-8
94. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355(19):1967-77
95. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009;69(11):1483-512
96. Hartmann EL, Gatesman M, Roskopf-Somerville J, et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant 2008;22(6):822-8
97. Hurst FP, Belur P, Nee R, et al. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System. Transplantation 2011;92(1):36-40
98. Keown P, Landsberg D, Halloran P, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62(12):1744-52
99. Smith EP. Hematologic disorders after solid organ transplantation. Hematology Am Soc Hematol Educ Program 2010;2010:281-6
100. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4(12):2001-6
101. Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis and sirolimus-is iron the missing link? Nephrol Dial Transplant 2010; 25(5):1667-75
102. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009;9(5):1087-98
103. Rangel EB, Gonzalez AM, Linhares MM, et al. Thrombotic microangiopathy after simultaneous pancreas-kidney transplantation. Clin Transplant 2007;21(2):241-5
104. Senzolo M, Ferronato C, Burra P. Neurologic complications after solid organ transplantation. Transpl Int 2009; 22(3):269-78
105. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13(5):313-26
106. Kiok MC. Neurologic complications of pancreas transplants. Neurol Clin 1988; 6(2):367-76
107. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246(5):339-46
108. Bartynski WS, Tan HP, Boardman JF, et al. Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 2008;29(5):924-30
109. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49(6):356-63
110. van Gelder T, ter Meulen CG, Hené R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75(6):788-91
111. Karbowska A, Boratynska M, Kusztal M, Klinger M. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant Proc 2009;41(8):3052-5
112. Bandukwala F, Huang M, Zaltzman JS, et al. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol 2009;103(6):867-71
113. Armstrong KA, Johnson DW, Campbell SB, et al. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation 2005; 80(11):1565-71
114. Lin HY, Rocher LL, McQuillan et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989;321(5):287-92
115. Kanbay M, Akcay A, Huddam B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005;37(7):3119-20
116. A, HaririanNogueira JM, Zandi-Nejad K, et al. The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation 2010;89(5):573-9
117. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351(6):585-92
118. Rangel EB, Gomes SA, Machado PG, et al. Severe hyperkalemic type 4 renal tubular acidosis after kidney transplantation: a case report. Transplant Proc 2006;38(9):3112-15
119. Anderka MT, Lin AE, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009;149A(6):1241-8
120. Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008;8(7):1471-9
121. Alfadhli E, Koh A, Albaker W, et al. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transpl In 2009; 22(6):622-5
122. Shivaswamy V, Ochsner L, Maroni D, et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. Transplantation 2011;91(12):1333-9
123. Deshpande NA, James NT, Kucirka LM, et al. Pregnancy outcomes in kidney transplant recipients: a systematic review and meta-analysis. Am J Transplant 2011;11(11):2388-404
124. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2004; 103-14
125. Lessan-Pezeshki M. Pregnancy after renal transplantation: points to consider. Nephrol Dial Transplant 2002; 17(5):703-7
126. Pai RP, Mitchell P, Chow VC, et al. Posttransplant cataract: lessons from kidney-pancreas transplantation. Transplantation 2000;69(6):1108-14
127. Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature. Nephrol Dial Transplant 2007;22(12):3631-7
128. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80(6):565-81
129. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48
130. McAlister VC, Mahalati K, Peltekian KM, et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002;24:346
131. Grinyó JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009;24(7):2269-76
132. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004;309(3):1029-35
133. Kuypers DR, Le Meur Y, Cantarovich M, et al. Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010;5(2):341-58
134. D, AnglicheauFlamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18(11):2409-14
135. Rajab A, Pelletier RP, Ferguson RM, et al. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients. Transplantation 2007; 84(9):1131-7
136. Knight RJ, Kerman RH, McKissick E, et al. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Clin Transplant 2008;22(5):645-50
137. Knight RJ, Podder H, Kerman RH, et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Transplantation 2010;89(6):727-32
138. Rangel EB;Belatacept in clinical and experimental transplantation- progress and promise. Drugs Today (Barc) 2010;46(4):235-42